The glucagon-like peptide 1 (GLP-1) market is poised for growth due to rising diabetes and obesity rates, expanded therapy ...

A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction – and help people who already have one, a new study shows. Semaglutide (also known as Ozempic) ...

Use of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced risk of developing substance use disorders among US veterans with type 2 diabetes. Evidence Rating Level: 2 (Good) ...

GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance ...

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...

Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor ...

GLP-1 receptor agonists like semaglutide are being used off-label by healthy people hoping to slow ageing, despite limited evidence and unknown long-term risks.

Combining GLP-1 medications with 8 healthy lifestyle habits reduced the risk of major adverse cardiovascular events, or MACE, ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and ...